Organization | DuPont Merck

DuPont Merck Report issue

Contributed to NME For profit Phase 2 Phase 3

Founded: Wilmington DE United States (1991)

Status: Acquired by DuPont (1998) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial

1998

NCT00375388

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1999

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dupont Merck

Active Ingredients

Drugs in Phase 3 Trials (5)

efavirenz (sustiva) (3 trials)

indinavir (crixivan) (2 trials)

lamivudine (epivir) (2 trials)

sitagliptin (januvia) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 2 Trials (2)

didanosine (videx) (1 trial)

stavudine (zerit) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

HIV Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 7